Polyphor AG

  • ISIN: CH0106213793
  • Land: Schweiz

Weblinks

Polyphor extends clinical development portfolio by advancing its inhaled elastase inhibitor POL6014 for lung diseases to Phase I
20150917 Polyphor_Taisho_PR_final
20151201 Polyphor_PR_Novartis
20151222 Polyphor_PR_Boehringer
Polyphor announces $3 Million Award from Cystic Fibrosis Foundation Therapeutics to advance the clinical development of POL6014
Polyphor successfully completes clinical Phase I study with POL6014 targeting life threatening lung diseases including cystic fibrosis
Polyphor and Gilead establish R&D macrocycle drug discovery collaboration
Giacomo di Nepi wird CEO
Giacomo Di Nepi appointed new CEO
Polyphor achieves milestone
Polyphor achieves milestone in Taisho collaboration
Forschungsgelder von Wellcome Trust
Award Wellcome Trust
New CMDO Appointed
Polyphor announces closing of CHF 40 million private financing round
Poyphor_ECCM Congress
Polyphor_ECCMID Congress
Polyphor_ECCMID_OMPTA
Polyphor_EDDMID_OMPTA
Polyphor announces successful end of phase II meeting with FDA for Murepavadin in nosocomial pneumonia
Kalina Scott appointed new CFO of Polyphor
Neutrophil Elastase Science
Polyphor achieves ahead of schedule first milestone from Wellcome Trust for the development of novel antibiotics against Gram-negative multidrug – resistant pathogens
Polyphor AG: Polyphor launches the development of an inhaled formulation of its antibiotic Murepavadin and joins a European consortium of leading hospitals and research institutions
Polyphor_Press Release_AMR_23012018
Mediarelease Polyphor Santhera 15 02 2018
Mediarelease_Polyphor_Santhera_Feb 15_2018_D
Mediarelease_Polyphor_Mar 08_2018_Balixafortide_FDA Meeting_D
Mediarelease_Polyphor_Mar 08_2018_Balixafortide_FDA Meeting_E
Polyphor präsentiert positive Proof-of-Concept-Daten auf der European Breast Cancer Conference für den innovativen Immunonkologie-Kandidaten Balixafortide
Polyphor presents positive proof of concept data for innovative immuno-oncology candidate balixafortide at European Breast Cancer Conference
Polyphor_Murepavadin_First Patient
Polyphor_Murepavadin_Erste Patient
Polyphor schliesst Kooperation mit Wellcome Trust zur Entwicklung neuartiger Antibiotika gegen multiresistente gramnegative Krankheitserreger erfolgreich ab
Polyphor successfully completes Wellcome Trust collaboration for development of novel antibiotics against multi-drug resistant Gram-negative pathogens
Polyphor präsentiert Daten auf dem 28. Europäischen Kongress für klinische Mikrobiologie
Polyphor to present data at the 28th European Congress of Clinical Microbiology
Balixafortide 19042018
Balixafortide 19042018
20180424 Polyphor Press Release ECCMID Data
20180424 Polyphor Press Release ECCMID Data
Polyphor Balixafortide Lancet 20180430
Polyphor Balixafortide Lancet 20180430
POLN_WT new shares_17.7.2018
Polyphor_Novo REPAIR Fund_PR_6.9.2018
Polyphor_Novo REPAIR Fund_6.9.2018
Polyphor_HY18 Results_6.9.2018
Polyphor_HY18 Results_9.6.2018
Polyphor_ESMO_18.10.2018
Polyphor_CMDO_PR_24.10.2018
Polyphor_Murepavadin_PRIDM_UDR_24.10.2018
Polyphor_Balixafortide_ESMO_24.10.2018
Polyphor_Swiss Technology Award_23.11.2018
Polyphor_Swiss Technology Award_23.11.2018
Poyphor_Balixafortide_FDA_3.12.2018
Polyphor_Balixafortide_FDA_3.12.2018

News im Fokus

Deutsche Post AG: Deutsche Post AG nimmt Stellung zur beabsichtigten Entscheidung zur Preisregulierung

15. Januar 2019, 13:37

Aktuelle Research-Studie

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Kaufen Valneva SE

17. Januar 2019